Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 352

1.

Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention.

Pencina KM, Thanassoulis G, Wilkins JT, Vasan RS, Navar AM, Peterson ED, Pencina MJ, Sniderman AD.

J Am Coll Cardiol. 2019 Jul 9;74(1):70-79. doi: 10.1016/j.jacc.2019.04.047.

PMID:
31272554
2.

Did the ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA cholesterol guidelines get apoB right?

Sniderman AD.

J Clin Lipidol. 2019 May - Jun;13(3):360-366. doi: 10.1016/j.jacl.2019.05.010. No abstract available.

PMID:
31229023
3.

ApoB.

Sniderman AD, Pencina M, Thanassoulis G.

Circ Res. 2019 May 10;124(10):1425-1427. doi: 10.1161/CIRCRESAHA.119.315019. No abstract available.

PMID:
31070997
4.

Quantifying Importance of Major Risk Factors for Coronary Heart Disease.

Pencina MJ, Navar AM, Wojdyla D, Sanchez RJ, Khan I, Elassal J, D'Agostino RB Sr, Peterson ED, Sniderman AD.

Circulation. 2019 Mar 26;139(13):1603-1611. doi: 10.1161/CIRCULATIONAHA.117.031855.

5.

Type III Hyperlipoproteinemia: The Forgotten, Disregarded, Neglected, Overlooked, Ignored but Highly Atherogenic, and Highly Treatable Dyslipoproteinemia.

Sniderman AD.

Clin Chem. 2019 Feb;65(2):225-227. doi: 10.1373/clinchem.2018.298026. Epub 2018 Dec 11. No abstract available.

PMID:
30538123
6.

ApoB in clinical care: Pro and Con.

Sniderman AD, Robinson JG.

Atherosclerosis. 2019 Mar;282:169-175. doi: 10.1016/j.atherosclerosis.2018.11.001. Epub 2018 Nov 10. Review.

PMID:
30463677
7.

A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.

Thanassoulis G, Sniderman AD, Pencina MJ.

JAMA Cardiol. 2018 Nov 1;3(11):1090-1095. doi: 10.1001/jamacardio.2018.3476.

PMID:
30422172
8.

Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated.

Sniderman AD, Thanassoulis G, Wilkins JT, Furberg CD, Pencina M.

J Am Heart Assoc. 2018 Oct 2;7(19):e010049. doi: 10.1161/JAHA.118.010049. No abstract available.

9.

Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life.

Robinson JG, Williams KJ, Gidding S, Borén J, Tabas I, Fisher EA, Packard C, Pencina M, Fayad ZA, Mani V, Rye KA, Nordestgaard BG, Tybjærg-Hansen A, Douglas PS, Nicholls SJ, Pagidipati N, Sniderman A.

J Am Heart Assoc. 2018 Oct 16;7(20):e009778. doi: 10.1161/JAHA.118.009778. No abstract available.

10.

The spectrum of type III hyperlipoproteinemia.

Sniderman AD, de Graaf J, Thanassoulis G, Tremblay AJ, Martin SS, Couture P.

J Clin Lipidol. 2018 Nov - Dec;12(6):1383-1389. doi: 10.1016/j.jacl.2018.09.006. Epub 2018 Sep 14.

PMID:
30318453
11.

A failure of standardization or a failure of the process of standardization.

Sniderman AD, McQueen MJ.

J Clin Lipidol. 2018 Sep - Oct;12(5):1325-1326. doi: 10.1016/j.jacl.2018.05.009. Epub 2018 May 18. No abstract available.

PMID:
30318067
12.

Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.

Sniderman AD, Couture P, Martin SS, DeGraaf J, Lawler PR, Cromwell WC, Wilkins JT, Thanassoulis G.

J Lipid Res. 2018 Jul;59(7):1266-1275. doi: 10.1194/jlr.R082271. Epub 2018 May 16.

13.

Response by Labos et al to Letter Regarding Article, "Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression".

Labos C, Brophy JM, Smith GD, Sniderman AD, Thanassoulis G.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):e87-e88. doi: 10.1161/ATVBAHA.118.310907. No abstract available.

PMID:
29695535
14.

A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux Capacity.

Seckler HDS, Fornelli L, Mutharasan RK, Thaxton CS, Fellers R, Daviglus M, Sniderman A, Rader D, Kelleher NL, Lloyd-Jones DM, Compton PD, Wilkins JT.

J Proteome Res. 2018 Jun 1;17(6):2156-2164. doi: 10.1021/acs.jproteome.8b00100. Epub 2018 Apr 27.

15.

Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression-Brief Report.

Labos C, Brophy JM, Smith GD, Sniderman AD, Thanassoulis G.

Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):262-265. doi: 10.1161/ATVBAHA.117.310052. Epub 2017 Nov 9.

PMID:
29122815
16.

Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.

Burstein B, Altobelli KK, Williams K, Cannon CP, Pencina MJ, Sniderman AD, Thanassoulis G.

Circulation. 2017 Nov 7;136(19):1860-1862. doi: 10.1161/CIRCULATIONAHA.117.029102. No abstract available.

PMID:
29109198
17.

Race and Socioeconomic Differences Associated With Changes in Statin Eligibility Under the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.

Verma AA, Jimenez MP, Subramanian SV, Sniderman AD, Razak F.

Circ Cardiovasc Qual Outcomes. 2017 Sep;10(9). pii: e003764. doi: 10.1161/CIRCOUTCOMES.117.003764.

PMID:
28912201
18.

Genetic Studies Help Clarify the Complexities of Lipid Biology and Treatment.

Sniderman AD, Peterson ED.

JAMA. 2017 Sep 12;318(10):915-917. doi: 10.1001/jama.2017.11750. No abstract available.

PMID:
28846117
19.

Shunts, channels and lipoprotein endosomal traffic: a new model of cholesterol homeostasis in the hepatocyte.

Scott Kiss R, Sniderman A.

J Biomed Res. 2017 Jan 19;31(2):95-107. doi: 10.7555/JBR.31.20160139.

20.

The Benefit Model for Prevention of Cardiovascular Disease: An Opportunity to Harmonize Guidelines.

Thanassoulis G, Pencina MJ, Sniderman AD.

JAMA Cardiol. 2017 Nov 1;2(11):1175-1176. doi: 10.1001/jamacardio.2017.2543. No abstract available.

PMID:
28793137
21.

World Heart Federation Cholesterol Roadmap.

Murphy A, Faria-Neto JR, Al-Rasadi K, Blom D, Catapano A, Cuevas A, Lopez-Jimenez F, Perel P, Santos R, Sniderman A, Sy R, Watts GF, Zhao D, Yusuf S, Wood D.

Glob Heart. 2017 Sep;12(3):179-197.e5. doi: 10.1016/j.gheart.2017.03.002. Epub 2017 Jul 29. Review.

PMID:
28765036
22.

Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte.

Sniderman AD, Kiss RS, Reid T, Thanassoulis G, Watts GF.

Clin Sci (Lond). 2017 May 1;131(9):791-797. doi: 10.1042/CS20160872.

PMID:
28424373
23.

Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines.

Pagidipati NJ, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ.

JAMA. 2017 Apr 18;317(15):1563-1567. doi: 10.1001/jama.2017.3416.

24.

Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women.

Lawler PR, Akinkuolie AO, Ridker PM, Sniderman AD, Buring JE, Glynn RJ, Chasman DI, Mora S.

Clin Chem. 2017 Apr;63(4):870-879. doi: 10.1373/clinchem.2016.264515. Epub 2017 Feb 7.

25.

Variants in ANGPTL4 and the Risk of Coronary Artery Disease.

Sniderman AD, Thanassoulis G.

N Engl J Med. 2016 Dec 8;375(23):2304. doi: 10.1056/NEJMc1607380. No abstract available.

PMID:
27959692
26.

Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence.

Navar AM, Peterson ED, Wojdyla D, Sanchez RJ, Sniderman AD, D'Agostino RB Sr, Pencina MJ.

JAMA. 2016 Nov 15;316(19):2041-2043. doi: 10.1001/jama.2016.13614. No abstract available. Erratum in: JAMA. 2016 Dec 13;316(22):2433.

27.

Nutritional management of hyperapoB.

Lamantia V, Sniderman A, Faraj M.

Nutr Res Rev. 2016 Dec;29(2):202-233. Epub 2016 Nov 8. Review.

PMID:
27821191
28.

Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis-Brief Report.

Afshar M, Kamstrup PR, Williams K, Sniderman AD, Nordestgaard BG, Thanassoulis G.

Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2421-2423. Epub 2016 Oct 20.

PMID:
27765771
29.

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low-Density Lipoprotein Cholesterol or Non-High-Density Lipoprotein Cholesterol.

Sniderman AD, Islam S, McQueen M, Pencina M, Furberg CD, Thanassoulis G, Yusuf S.

J Am Heart Assoc. 2016 Oct 13;5(10). pii: e003665.

30.

Serial versus single troponin measurements for the prediction of cardiovascular events and mortality in stable chronic haemodialysis patients.

Mavrakanas TA, Sniderman AD, Barré PE, Alam A.

Nephrology (Carlton). 2018 Jan;23(1):69-74. doi: 10.1111/nep.12945.

PMID:
27718506
31.

An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB.

Sniderman AD, Toth PP, Thanassoulis G, Furberg CD.

J Clin Lipidol. 2016 Sep-Oct;10(5):1248-58. doi: 10.1016/j.jacl.2016.07.008. Epub 2016 Aug 2.

PMID:
27678443
32.

Risk of Premature Cardiovascular Disease vs the Number of Premature Cardiovascular Events.

Sniderman AD, Thanassoulis G, Williams K, Pencina M.

JAMA Cardiol. 2016 Jul 1;1(4):492-4. doi: 10.1001/jamacardio.2016.0991. No abstract available.

PMID:
27438330
33.

The Enigma of Glucose and Lipid Metabolism.

Pagidipati NJ, Pencina M, Sniderman AD.

JAMA Cardiol. 2016 May 1;1(2):145-6. doi: 10.1001/jamacardio.2016.0183. No abstract available.

PMID:
27437884
34.

Reply: Clinical Significance and Potential Mechanism of Discordance Between Apolipoprotein B and LDL-Cholesterol.

Wilkins JT, Sniderman A, Lloyd-Jones DM.

J Am Coll Cardiol. 2016 Jun 28;67(25):3024-5. doi: 10.1016/j.jacc.2016.03.579. No abstract available.

35.

High Ultrafiltration Rates Increase Troponin Levels in Stable Hemodialysis Patients.

Mavrakanas TA, Sniderman AD, Barré PE, Vasilevsky M, Alam A.

Am J Nephrol. 2016;43(3):173-8. doi: 10.1159/000445360. Epub 2016 Apr 12.

PMID:
27064739
36.

Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease.

Thanassoulis G, Williams K, Altobelli KK, Pencina MJ, Cannon CP, Sniderman AD.

Circulation. 2016 Apr 19;133(16):1574-81. doi: 10.1161/CIRCULATIONAHA.115.018383. Epub 2016 Mar 4.

PMID:
26945047
37.

Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification: The CARDIA Study.

Wilkins JT, Li RC, Sniderman A, Chan C, Lloyd-Jones DM.

J Am Coll Cardiol. 2016 Jan 19;67(2):193-201. doi: 10.1016/j.jacc.2015.10.055.

38.

JCL roundtable: Apolipoproteins as causative elements in vascular disease.

Brown WV, Sacks FM, Sniderman AD.

J Clin Lipidol. 2015 Nov-Dec;9(6):733-740. doi: 10.1016/j.jacl.2015.10.003. Epub 2015 Oct 22. Review.

PMID:
26687693
39.

Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis.

Sahebkar A, Serban MC, Mikhailidis DP, Toth PP, Muntner P, Ursoniu S, Mosterou S, Glasser S, Martin SS, Jones SR, Rizzo M, Rysz J, Sniderman AD, Pencina MJ, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group.

Pharmacol Res. 2016 Jan;103:236-52. doi: 10.1016/j.phrs.2015.12.001. Epub 2015 Dec 3. Review.

PMID:
26657419
40.

Risk Prediction for Individuals--Reply.

Sniderman AD, D'Agostino RB Sr, Pencina MJ.

JAMA. 2015 Nov 3;314(17):1875-6. doi: 10.1001/jama.2015.12221. No abstract available.

PMID:
26529170
41.

Response to Letter Regarding Article, "Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease".

Navar-Boggan AM, Peterson ED, D'Agostino RB Sr, Neely B, Sniderman AD, Pencina MJ.

Circulation. 2015 Oct 20;132(16):e203. doi: 10.1161/CIRCULATIONAHA.115.017048. No abstract available.

PMID:
26481569
42.

Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9.

Quispe R, Al-Hijji M, Swiger KJ, Martin SS, Elshazly MB, Blaha MJ, Joshi PH, Blumenthal RS, Sniderman AD, Toth PP, Jones SR.

J Clin Lipidol. 2015 Jul-Aug;9(4):511-8.e1-5. doi: 10.1016/j.jacl.2015.05.005. Epub 2015 Jun 19.

PMID:
26228668
43.

The Role of Physicians in the Era of Predictive Analytics.

Sniderman AD, D'Agostino RB Sr, Pencina MJ.

JAMA. 2015 Jul 7;314(1):25-6. doi: 10.1001/jama.2015.6177. No abstract available.

PMID:
26151261
44.

Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol: The Very Large Database of Lipids Study (VLDL-2B).

Elshazly MB, Quispe R, Michos ED, Sniderman AD, Toth PP, Banach M, Kulkarni KR, Coresh J, Blumenthal RS, Jones SR, Martin SS.

Circulation. 2015 Aug 25;132(8):667-76. doi: 10.1161/CIRCULATIONAHA.115.016163. Epub 2015 Jul 2.

45.

Is the Guideline Process Replicable and, if Not, What Does This Mean?

Sniderman A, Furberg CD, Toth PP, Thanassoulis G.

Prog Cardiovasc Dis. 2015 Jul-Aug;58(1):3-9. doi: 10.1016/j.pcad.2015.05.002. Epub 2015 May 7. Review.

PMID:
25958015
46.

Screening Strategies and Primary Prevention Interventions in Relatives of People With Coronary Artery Disease: A Systematic Review and Meta-analysis.

Goldfarb M, Slobod D, Dufresne L, Brophy JM, Sniderman A, Thanassoulis G.

Can J Cardiol. 2015 May;31(5):649-57. doi: 10.1016/j.cjca.2015.02.019. Epub 2015 Feb 20. Review.

PMID:
25936490
47.

Limitations in the conventional assessment of the incremental value of predictors of cardiovascular risk.

Sniderman AD, Pencina M, Thanassoulis G.

Curr Opin Lipidol. 2015 Jun;26(3):210-4. doi: 10.1097/MOL.0000000000000181. Review.

PMID:
25887681
48.
49.

Using age- and sex-specific risk thresholds to guide statin therapy: one size may not fit all.

Navar-Boggan AM, Peterson ED, D'Agostino RB Sr, Pencina MJ, Sniderman AD.

J Am Coll Cardiol. 2015 Apr 28;65(16):1633-1639. doi: 10.1016/j.jacc.2015.02.025. Epub 2015 Mar 2.

50.

Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C.

Pencina MJ, D'Agostino RB, Zdrojewski T, Williams K, Thanassoulis G, Furberg CD, Peterson ED, Vasan RS, Sniderman AD.

Eur J Prev Cardiol. 2015 Oct;22(10):1321-7. doi: 10.1177/2047487315569411. Epub 2015 Jan 29.

PMID:
25633587

Supplemental Content

Loading ...
Support Center